NeuroNEXT’s Multicenter Trial of Rituximab in Myasthenia Gravis Announces Addition of Clinical Study Sites

Tuesday, March 3, 2015

The NN103 Study Team is pleased to announce the addition of 11 NeuroNEXT Clinical Study Sites (CSS) across the US. One CSS has already been activated for enrollment, and 10 more are in the process of being activated. This will bring the total number of enrolling clinical study sites to 26.

**Study Description:**

*A Phase 2 Trial of Rituximab in Myasthenia Gravis (NN103)*

The purpose of this trial is to learn if rituximab is a safe and effective drug for people with myasthenia gravis (MG). This trial also will determine if rituximab will allow people with MG to decrease their prednisone dosage or discontinue prednisone treatment.

This randomized, placebo-controlled study will determine the safety, tolerability and benefit of rituximab in patients with MG. Fifty people will enroll in this trial at sites across the U.S. Participants will receive either rituximab or a placebo (an inactive substance) administered in two 4-week cycles. The cycles will be separated by 6 months. Participants will have regular study visits every 4 weeks which will include MG-focused physical examinations, blood draws, and questionnaires. Study duration for participants is 52 weeks. The trial also will examine immunological changes that may occur during treatment in an effort to help develop future patient-tailored therapies.

This trial is coordinated by NeuroNEXT (the Network for Excellence in Neuroscience Clinical Trials) with support and funding from the National Institute of Neurological Disorders and Stroke (NINDS). Study drug is being provided by Genentech.

**Please see below for additional study details and complete site listing:**

- Clinicaltrial.gov [NCT02110706](https://clinicaltrials.gov/ct2/show/NCT02110706)
- NeuroNEXT [NN103 Project Page](https://www.neuronext.org/nn103/)

For more information about about the study or if you are interested in participating, please contact: [MGstudy@yale.edu](mailto:MGstudy@yale.edu), or call 1-844-MGSTUDY (1-844-647-8839).